

Treatment For Lung Cancer

Reference Number: F4878
Date of Response: 20/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib – **0 patients**
- Alectinib – **5 patients**
- Atezolizumab monotherapy – *** patients**
- Atezolizumab in combination – *** <5 patients**
- Bevacizumab – **0 patients**
- Brigatinib – **0 patients**
- Capmatenib – **0 patients**
- Ceritinib – **0 patients**
- Crizotinib – *** patients**
- Dacomitinib – **0 patients**
- Dabrafenib with Trametinib – *** <5 patients**
- Docetaxel monotherapy – **0 patients**
- Durvalumab – **0 patients**
- Erlotinib – *** patients**
- Gefitinib – **0 patients**
- Gemcitabine – **0 patients**
- Nintedanib with Docetaxel – *** <5 patients**

- Nivolumab – **0 patients**
- Osimertinib – **15 patients**
- Paclitaxel – **0 patients**
- Pembrolizumab monotherapy – **15 patients**
- Pembrolizumab in combination – **14 patients**
- Pemetrexed with Carboplatin/Cisplatin – *** patients**
- Tepotinib – **0 patients**
- Vinorelbine with Cisplatin/Carboplatin – *** <5 patients**
- Any other SACT – **6 patients**
- Palliative care only – **0 patients**

***-<5 Low number suppressed to protect patient identity.**

***≤5. In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.**